Editorial
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Dec 14, 2008; 14(46): 7021-7032
Published online Dec 14, 2008. doi: 10.3748/wjg.14.7021
Table 1 Current status of clinical trials with agents that target growth factor receptors and related signaling pathways for treatment of biliary tract and gallbladder cancers
NameTargetMechanismCotreatmentStatusClinical trials
BevacizumabVEGFVEGF-neutralizing antibodyErlotinibPhase IINCT00350753[17]
ErlotinibPhase IINCT00356889[18]
RadiationPhase INCT00426829[21]
Floxuridine, dexamethasonePhase IINCT00410956[20]
Gemcitabine, oxaliplatinPhase IINCT00361231[19]
Cediranib (AZD2171)PAN-VEGFR, PDGFR, c-KITTyrosine kinase inhibitorAZD-0530Phase INCT00475956
CetuximabEGFRMonoclonal antibodyGemcitabine, oxaliplatinPhase IINCT00552149 (BINGO)[22]
ErlotinibEGFRTyrosine kinase inhibitorPhase IINCT00033462[12]
GemcitabinePhase Ib
Oxaliplatin, gemcitabine, radiationPhase INCT00266097[16]
LapatinibEGFR, erbB2Tyrosine kinase inhibitorPhase IINCT00107536[14]
SorafenibVEGFR, PDGFR, c-Raf, B-RafTyrosine kinase inhibitorOxaliplatin,Phase IINCT00238212[15]
CapecitabinePhase I/IINCT00634751[23]
GemcitabinePhase I/IINCT00661830 (GEMSO)[24]
BortezomibProteasomeProteasome inhibitorPhase IINCT00085410[13]
DocetaxelPhase I